VP16-213 as a single agent in advanced testicular tumors
- 1 September 1980
- journal article
- research article
- Published by Elsevier in European Journal of Cancer (1965)
- Vol. 16 (9), 1193-1197
- https://doi.org/10.1016/0014-2964(80)90178-4
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- EPIPODOPHYLLIN DERIVATIVE (VP 16-213) IN TREATMENT OF SOLID TUMOURSThe Lancet, 1977
- EPIPODOPHYLLIN DERIVATIVE (VP 16-213) IN MALIGNANT TERATOMAS AND CHORIOCARCINOMASThe Lancet, 1977
- Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cellsBiochemistry, 1976
- VP 16-213 in acute myelogenous leukaemiaPublished by Oxford University Press (OUP) ,1976
- Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia.BMJ, 1975
- A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213Cancer, 1975
- Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomasCancer, 1974
- Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia--Haematosarcoma and Solid TumoursBMJ, 1973
- Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumorsEuropean Journal of Cancer (1965), 1973
- CHEMOTHERAPY FOR METASTATIC TERATOMAS OF THE TESTISBritish Journal of Urology, 1972